cancer is the fourth most leading causes of cancer-related deaths worldwide
accounting for nearly 7-10% of all cancers. Colon cancer treatment remains
challenging especially that chemotherapy results in adverse outcomes on
patients’ health. Adoptive T Cell Therapy (ACT) is a new type of immunotherapy
that relies on isolating, culturing and re-injecting patients’ own CD8 T cells.
This is the first study to determine the effect of ACT alone or in adjunct to
Sorafenib on the Vascular Endothelial Growth Factor (VEGF) signaling pathway in
DMH-induced colon cancer in Balb/c mice.
To read the full study, please CLICK HERE.